Clinical study of enema aplication of Yiyi-Fuzi-Baijiang powder combined with oral sulfasalazine in treating ulcerative colitis
10.3760/cma.j.issn.1673-4246.2017.03.009
- VernacularTitle:薏苡附子败酱散保留灌肠结合柳氮磺胺吡啶治疗溃疡性结肠炎临床研究
- Author:
Yuan YUAN
- Keywords:
Colitis;
ulcerative;
Yiyi-Fuzi-Baijiang powder;
Retention enema;
Interleukin-6;
Interleukin-8;
Tumor necrosis factor-alpha
- From:
International Journal of Traditional Chinese Medicine
2017;39(3):221-224
- CountryChina
- Language:Chinese
-
Abstract:
Objective Evaluation of enema application of Yiyi-Fuzi-Baijiang powder combined with oral sulfasalazine enteric-coated tablets in treating ulcerative colitis. Methods The patients with ulcerative colitis were randomly divided into 2 groups, 42 cases in each group. The control group was treated with sulfasalazine, and the observation group with sulfasalazine and Yiyi-Fuzi-Baijiang powder. Both groups were treated for 4 weeks. ELISA method was used to detect the levels of IL-6, IL-8 and TNF-α. The changes of disease activity index (Sutherland DAI) were observed before and after treatment, and the clinical efficacy was evaluated. Results After treatment, the Sutherland DAI (3.89 ± 0.91 vs. 4.91 ± 1.08, t=3.082) in the observation group was significantly lower than that in the control group (P=0.042). The level of TNF-α (20.82 ± 4.31 ng/L vs. 26.51 ± 5.25 ng/L, t=3.602), IL-6 (31.73 ± 4.82 ng/L vs. 40.18 ± 5.63 ng/L, t=3.817), and IL-8 (35.39 ± 4.62 ng/L vs. 40.59 ± 5.35 ng/L, t=3.341) in the observation group were significantly lower than those in the control group (P<0.05). The total efficiency of observation group was 92.9% (39/42), and the control group was 73.8% (31/42). There was significant difference between the two groups (χ2=4.200, P=0.040). Conclusions The Yiyi-Fuzi-Baijiang powder combined with sulfasalazine could relieve the clinical symptoms of ulcerative colitis patients with spleen-kidney yang deficiency, and inhibition inflammatory response.
